D A Vallera
Overview
Explore the profile of D A Vallera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
135
Citations
1251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmohl J, Gleason M, Dougherty P, Miller J, Vallera D
Target Oncol
. 2015 Nov;
11(3):353-61.
PMID: 26566946
Background: Natural killer (NK) cells are potent cytotoxic lymphocytes that play a critical role in tumor immunosurveillance and control. Cancer stem cells (CSC) initiate and sustain tumor cell growth, mediate...
2.
Stish B, Oh S, Chen H, Dudek A, Kratzke R, Vallera D
Br J Cancer
. 2009 Sep;
101(7):1114-23.
PMID: 19755995
Background: Potency, immunogenicity, and toxicity are three problems that limit the use of targeted toxins in solid tumour therapy. Methods: To address potency, we used genetic engineering to develop a...
3.
Vallera D, Stish B, Shu Y, Chen H, Saluja A, Buchsbaum D, et al.
Gut
. 2008 Jan;
57(5):634-41.
PMID: 18222985
Objective: Investigators are currently interested in the epidermal growth factor receptor (EGFR) and interleukin 13 receptor (IL13R) as potential targets in the development of new biologicals for pancreatic cancer. Attempts...
4.
Kim K, Vallera D, Ni H, Cho K, Low W, Hall W
Neurosurg Focus
. 2006 Jul;
9(6):e5.
PMID: 16817688
Object: The prognosis for patients with primary malignant brain tumors is poor despite aggressive treatment, and tumor recurrence is common regardless of the chosen therapy. Although multimodal treatment does not...
5.
Vallera D, ELSON M, Brechbiel M, Dusenbery K, Burns L, Skubitz K, et al.
Cancer Biother Radiopharm
. 2003 Jun;
18(2):133-45.
PMID: 12804039
A study was undertaken to investigate the suitability of using a high affinity (Kd = 1.1 nM) anti-CD45 monoclonal antibody for delivering the high energy beta-particle emitting isotope (90)Y to...
6.
Frankel A, Powell B, Vallera D, Neville Jr D
Curr Opin Investig Drugs
. 2001 Nov;
2(9):1294-301.
PMID: 11717818
Most cancer patients receive chemotherapy drugs that target DNA or the cell division apparatus. Many of these patients develop multidrug-resistant tumor cells, thus, novel methods to overcome drug resistance are...
7.
8.
Vallera D, Kuroki D, Panoskaltsis-Mortari A, Buchsbaum D, Rogers B, Blazar B
Blood
. 2000 Jul;
96(3):1157-65.
PMID: 10910937
Immunotoxin (IT) therapy shows potential for selectively eliminating GVHD-causing T cells in vivo, but the field has been hampered by toxicity. Previously, we showed that a genetically engineered IT consisting...
9.
Vallera D, Jin N, Baldrica J, Panoskaltsis-Mortari A, Chen S, Blazar B
Cancer Res
. 2000 Mar;
60(4):976-84.
PMID: 10706113
The potential benefit of immunotoxin (IT) for cancer therapy has mostly been limited by the fact that only a small portion of injected dose ever reaches the cancer target. Thus,...
10.
Vallera D, Seo S, Panoskaltsis-Mortari A, Griffin J, Blazar B
Protein Eng
. 1999 Oct;
12(9):779-85.
PMID: 10506288
The IL-3 receptor was expressed on a high frequency of myeloid leukemia cells and also on hematopoietic and vascular cells. We previously showed that a recombinant IL-3 fusion immunotoxin (DT(390)IL-3)...